Pyxis Oncology, Inc.

PYXS

Pyxis Oncology, Inc.

PYXS

Insider Sentiment (TTM):

Last Purchase:2024-11-26Last Sale:2025-04-14Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:27,414,344Shares Outstanding:63,469,850Institutional Ownership Pct.:43.19%

Earnings Market Reaction:

Filing Date:2026-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	19	6	15	9	11	13	19	12	25	28	10	15
Marketable Securities Current	14	35	51	67	78	93	107	133	131	129	110	118
Restricted Cash Current	1	1	1	1	1	1	1	1	1	1	1	1
Accounts Receivable Net Current	-	-	-	-	3	-	-	-	-	8	-	-
Prepaid Expense Current	2	3	4	5	7	5	4	3	4	6	4	5
Assets Current	37	46	72	83	100	112	132	149	161	172	125	139
Property Plant And Equipment Net	7	8	8	8	9	9	10	10	11	11	12	12
Intangible Assets Net Excluding Goodwill	-	-	0	2	2	3	3	24	24	24	24	22
Operating Lease Right Of Use Asset	11	11	11	12	12	12	12	-	-	13	13	13
Assets	55	64	92	106	123	136	157	195	208	220	174	187
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	3	5	11	10	9	3	5	5	5	2	4	3
Accrued Liabilities Current	12	10	9	8	7	10	11	14	10	11	13	17
Operating Lease Liability Current	2	2	2	2	2	2	1	1	-	1	1	1
Contract With Customer Liability Current	-	-	-	-	-	-	-	-	-	-	8	7
Liabilities Current	27	17	21	19	18	14	18	20	17	14	26	28
Operating Lease Liability Noncurrent	16	16	17	17	18	18	19	19	19	20	20	20
Finance Lease Liability Noncurrent	-	0	0	0	0	0	0	0	0	-	-	-
Liabilities	43	33	38	37	36	33	36	42	39	36	48	49
Deferred Income Tax Liabilities Net	-	-	-	-	-	-	0	2	2	2	2	-
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	503	498	496	494	491	488	484	481	477	474	412	409
Accumulated Other Comprehensive Income Loss Net Of…	-0	0	0	0	-0	0	0	0	-0	-0	0	-0
Retained Earnings Accumulated Deficit	-492	-466	-443	-425	-403	-385	-364	-328	-307	-289	-286	-271
Stockholders Equity	11	31	53	69	88	103	121	154	170	184	126	138
Liabilities And Stockholders Equity	55	64	92	106	123	136	157	195	208	220	174	187
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0	0.001	0.001	0.001	0	0.001	0.001	0.001	0	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	190	190	190	190	190	190	190	190	190	190	190	190
Common Stock Shares Issued	63	63	63	62	62	62	60	59	59	59	45	44
Shares Outstanding	63	63	63	62	62	62	60	59	59	59	45	44

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-19.46%	19.00%	29.86%	-	-	-	-	-	-	-	-	-
2025	21.62%	-0.90%	-0.90%	69.03%	127.43%	215.04%	36.22%	-70.87%	-57.22%	16.90%	60.56%	23.94%
2024	-9.52%	-30.95%	-17.86%	4.17%	5.36%	11.90%	-63.85%	-63.20%	-66.02%	-9.53%	0.94%	27.36%
2023	-	-	-	-	-	-	-1.81%	8.43%	137.95%	-0.81%	-12.50%	-23.39%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	1.34	2.76	3.41	4.29	5.65	7.75	7.49	7.33	9.53	12.19	4.84	4.91
Quick Ratio	1.25	2.57	3.23	4.01	5.28	7.41	7.26	7.20	9.30	11.77	4.69	4.75
Working Capital	9.26M	29.04M	50.97M	63.69M	82.28M	97.44M	114.76M	128.55M	144.14M	158.24M	98.85M	110.76M
Leverage & Debt
Debt to Equity	3.80	1.06	0.71	0.54	0.41	0.32	0.30	0.27	0.23	0.20	0.38	0.35
Debt Ratio	0.79	0.51	0.42	0.35	0.29	0.24	0.23	0.21	0.19	0.16	0.28	0.26
Efficiency & Turnover
Asset Turnover TTM	0.12	0.14	0.11	0.04	0.02	0.00	0.10	0.08	0.08	0.08	0.00	0.00
Days Sales Outstanding TTM	-	-	-	-	388.30	-	-	-	-	180.85	-	-
Receivables Turnover TTM	-	-	-	-	0.94	-	-	-	-	2.02	-	-
Per Share Metrics
Diluted EPS TTM	-1.39	-1.29	-1.28	-1.55	-1.56	-1.56	-1.32	-0.94	-0.98	-1.13	-1.85	-2.28
Free Cash Flow Per Share TTM	-1.01	-1.06	-1.02	-0.80	-0.83	-0.98	-0.99	-0.89	-0.94	-1.31	-1.94	-1.97
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-834.44%	-619.61%	-609.18%	-1,882.87%	-3,776.13%	-	-554.07%	-415.94%	-425.85%	-414.02%	-	-
Net Profit Margin TTM	-803.83%	-589.80%	-574.55%	-1,721.38%	-3,414.40%	-	-478.95%	-355.24%	-366.67%	-358.00%	-	-
Growth Metrics
Net Revenue Growth (1Y)	291.42%	-	-14.17%	-65.07%	-82.53%	-100.00%	-	-	-	-	-	-
Net Income Growth (1Y)	-7.85%	-14.17%	2.96%	69.27%	62.64%	64.75%	4.80%	-39.17%	-40.15%	-46.76%	-38.87%	-35.60%
EPS Growth (1Y)	-10.84%	-17.45%	-3.16%	64.28%	58.90%	38.42%	-28.45%	-58.59%	-62.02%	-63.31%	-49.40%	-49.26%
Valuation Metrics
P/E TTM	-2.17	-1.13	-0.90	-1.43	-0.71	-0.63	-1.18	-3.88	-3.38	-3.78	-0.97	-0.87
P/B TTM	16.84	2.96	1.34	2.02	0.78	0.58	0.76	1.45	1.18	1.19	0.57	0.60
P/S TTM	17.45	6.69	5.16	24.62	24.15	-	5.65	13.80	12.40	13.53	-	-
Market Cap	192.61M	92.67M	71.46M	138.88M	68.11M	59.83M	91.18M	222.82M	200.24M	218.49M	71.83M	82.25M
Enterprise Value	173.76M	85.43M	56.07M	130.00M	55.97M	47.15M	71.80M	210.89M	173.83M	189.05M	62.16M	67.54M
Calculated Values
Free Cash Flow TTM	-64.45M	-66.98M	-63.51M	-49.84M	-51.46M	-59.73M	-58.15M	-54.11M	-56.85M	-67.14M	-77.44M	-81.43M
Net Debt	-18.86M	-7.24M	-15.40M	-8.88M	-12.14M	-12.68M	-19.37M	-11.94M	-26.41M	-29.44M	-9.66M	-14.72M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-04-14Sale

Owner: Humphrey, Rachel

Title: -

Shares: 1,400

Price/Share: $0.97

Value: $1,358.00

Shares Owned: 95,405

Relationship: Director

Ownership: Direct

2024-11-26Purchase

Owner: Connealy, Pamela Ann

Title: CFO & COO

Shares: 88,850

Price/Share: $1.98

Value: $175,923.00

Shares Owned: 1,199,143

Relationship: Officer

Ownership: Indirect

2023-09-28Purchase

Owner: Connealy, Pamela Ann

Title: CFO and COO

Shares: 8,000

Price/Share: $1.87

Value: $14,960.00

Shares Owned: 818,532

Relationship: Officer

Ownership: Direct

2023-09-27Purchase

Owner: Connealy, Pamela Ann

Title: CFO and COO

Shares: 6,426

Price/Share: $1.85

Value: $11,888.10

Shares Owned: 810,532

Relationship: Officer

Ownership: Direct

2023-09-27Purchase

Owner: Wadhane, Jitendra

Title: Chief Accounting Officer

Shares: 2,500

Price/Share: $1.87

Value: $4,675.00

Shares Owned: 226,937

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-04-14	Humphrey, Rachel	Director	-	Direct	Sale	1,400	0.97	$1,358.00	95,405	4
2024-11-26	Connealy, Pamela Ann	Officer	CFO & COO	Indirect	Purchase	88,850	1.98	$175,923.00	1,199,143	4
2023-09-28	Connealy, Pamela Ann	Officer	CFO and COO	Direct	Purchase	8,000	1.87	$14,960.00	818,532	4
2023-09-27	Connealy, Pamela Ann	Officer	CFO and COO	Direct	Purchase	6,426	1.85	$11,888.10	810,532	4
2023-09-27	Wadhane, Jitendra	Officer	Chief Accounting Officer	Direct	Purchase	2,500	1.87	$4,675.00	226,937	4
2023-09-25	Connealy, Pamela Ann	Officer	CFO and COO	Direct	Purchase	12,000	1.67	$20,040.00	804,106	4
2023-09-25	Wadhane, Jitendra	Officer	Chief Accounting Officer	Direct	Purchase	5,000	1.77	$8,850.00	224,437	4
2023-09-22	Connealy, Pamela Ann	Officer	CFO and COO	Direct	Purchase	5,000	1.74	$8,700.00	792,106	4
2023-09-22	Wadhane, Jitendra	Officer	Chief Accounting Officer	Direct	Purchase	2,500	1.74	$4,350.00	219,437	4
2023-09-18	Sullivan, Lara	Director,Officer	President and CEO	Direct	Sale	8,541	2.10	$17,936.10	2,403,882	4
2023-09-13	Sullivan, Lara	Director,Officer	President and CEO	Direct	Sale	3,000	2.27	$6,810.00	2,597,265	4
2023-03-17	Pfizer, Inc, Pfizer Ventu…	TenPercentOwner	-	Direct	Purchase	1,811,594	2.76	$4,999,999.44	5,952,263	4/A
2022-04-21	Chin, Mark	Other	-	Indirect	Sale	1,745,761	3.05	$5,324,571.05	0	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

43.19%

Inst. Shares: 27,414,344

Shares Outstanding: 63,469,850

2025-12-31

48.44%

Inst. Shares: 30,103,904

Shares Outstanding: 62,143,166

2025-09-30

42.67%

Inst. Shares: 26,696,244

Shares Outstanding: 62,557,386

2025-06-30

44.09%

Inst. Shares: 27,301,921

Shares Outstanding: 61,918,826

2025-03-31

49.18%

Inst. Shares: 30,024,273

Shares Outstanding: 61,048,948

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	27,414,344	63,469,850	43.19%
2025-12-31	30,103,904	62,143,166	48.44%
2025-09-30	26,696,244	62,557,386	42.67%
2025-06-30	27,301,921	61,918,826	44.09%
2025-03-31	30,024,273	61,048,948	49.18%
2024-12-31	31,405,964	58,445,765	53.74%
2024-09-30	27,739,151	60,715,041	45.69%
2024-06-30	27,878,856	60,495,675	46.08%
2024-03-31	22,500,986	51,289,284	43.87%
2023-12-31	8,359,174	39,904,603	20.95%
2023-09-30	6,704,950	41,331,806	16.22%
2023-06-30	9,021,344	38,389,123	23.50%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Pyxis Oncology, Inc. (PYXS) — SEC Financial Statements & Analysis

Pyxis Oncology, Inc. (PYXS) is a pharmaceutical preparations company, incorporated in DE. Pyxis Oncology, Inc. trades on Nasdaq as: PYXS. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Pyxis Oncology, Inc. reported a 291.42% year-over-year revenue growth, a Debt-to-Equity ratio of 3.80x, a Price-to-Sales (P/S) ratio of 17.45x (TTM), a Price-to-Book (P/B) ratio of 16.84x (TTM), at a market cap of $192.61M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 291.42%
Debt To Equity: 3.80x
P/S TTM: 17.45x
P/B TTM: 16.84x
Market Cap: $192.61M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Pyxis Oncology, Inc. in?

Pyxis Oncology, Inc. (PYXS) operates in the Pharmaceutical Preparations industry.

What is PYXS's market cap?

Pyxis Oncology, Inc. (PYXS) has a market capitalization of $192.61M as of 2026-06-30.

What exchange does PYXS trade on?

Pyxis Oncology, Inc. (PYXS) trades on the Nasdaq.

Where is Pyxis Oncology, Inc. incorporated?

Pyxis Oncology, Inc. is incorporated in DE.